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Abstract
TDP-43 and α-synuclein are two disease proteins involved in a wide range of neurodegenerative diseases. While TDP-43 proteinopathy is considered a pathologic hallmark of sporadic
amyotrophic lateral sclerosis and frontotemporal lobe degeneration, α-synuclein is a major
component of Lewy body characteristic of Parkinson’s disease. Intriguingly, TDP-43 proteinopathy also coexists with Lewy body and with synucleinopathy in certain disease conditions.
Here we reported the effects of TDP-43 on α-synuclein neurotoxicity in transgenic mice.
Overexpression of mutant TDP-43 (M337V substitution) in mice caused early death in
transgenic founders, but overexpression of normal TDP-43 only induced a moderate loss of
cortical neurons in the transgenic mice at advanced ages. Interestingly, concomitant overexpression of normal TDP-43 and mutant α-synuclein caused a more severe loss of dopaminergic neurons in the double transgenic mice as compared to single-gene transgenic mice.
TDP-43 potentiated α-synuclein toxicity to dopaminergic neurons in living animals. Our
finding provides in vivo evidence suggesting that disease proteins such as TDP-43 and
α-synuclein may play a synergistic role in disease induction in neurodegenerative diseases.
Key words: TDP-43; alpha-synuclein; mice; dopaminergic neuron; Parkinson’s disease; frontotemporal lobe degeneration, genetic model

1. Introduction
TAR DNA-binding protein 43 (TDP-43) is a
conserved ribonucleoprotein with diverse functions
as exemplified by the ability to regulate gene transcription, mRNA splicing, and RNA stability (1-6).
While its physiological functions remain to be elucidated, TDP-43 translocates to the cytoplasm and
forms ubiquitinated aggregates in neurodegenerative
diseases including amyotrophic lateral sclerosis (ALS)
and frontotemporal lobe degeneration (FTLD) (7-10).
TDP-43 proteinopathy, a hallmark of sporadic ALS
and FTLD, is also observed in the other neurodegenerative diseases such as Parkinson’s disease (PD) and

Alzheimer’s disease (11-13). Neurodegenerative diseases share some features in the pathogenesis and
pathology. Most cases of the diseases are sporadic and
only a small proportion of them have a clear genetic
cause. A neurodegenerative disease is characterized
by a selected group of neurons preferably affected at
early disease stages, but it often affects a wide range
of different neurons at advanced disease stages. For
example, heterogeneous neuropathology is observed
in sporadic ALS at advanced disease stages (14-16),
although motor neurons are preferably affected in the
disease at early disease stages. TDP-43 proteinopathy
http://www.biolsci.org
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is direct evidence supporting that neurodegenerative
diseases may be pathogenically interrelated.
While mutation in TDP-43 is linked to ALS and
FTLD (17-21), mutation of the α-synuclein gene is associated with PD (22-26). Overexpression of TDP-43
with or without pathogenic mutation causes a broad
neurodegeneration in rodents (27-32), suggesting that
normal TDP-43 of elevated expression is neurotoxic.
Overexpression of TDP-43 in the substantia nigra induces dopaminergic neuron death (33), suggesting
that TDP-43 neurotoxicity is not restricted to the
neurons preferably affected in ALS and FTLD. Overexpression of pathogenically mutated α-synuclein
causes dopaminergic neuron death in transgenic mice
at advanced ages (34). Neurodegenerative diseases
are commonly thought of multifactorial pathogenesis.
To test this hypothesis, we examined whether TDP-43
potentiates α-synuclein toxicity to dopaminergic
neurons in transgenic mice. Transgenic overexpression of the normal TDP-43 caused a significant loss of
neurons in the frontal cortex, but not in the substantia
nigra pars compacta (SNpc). When normal TDP-43
and mutant α-synuclein were overexpressed simultaneously in the dopaminergic neurons, a dramatic
loss of the neurons was detected in the SNpc of
transgenic mice. Our results suggest that neurotoxic
factors such as TDP-43 and α-synuclein may play a
synergistic role in the pathogenesis of neurodegenerative diseases.

2. Materials and Methods
Animal experiments
Animal use followed NIH guidelines and the
animal use protocol was approved by the Institutional
Animal Care and Use Committees at Thomas Jefferson University. As described in our publication (32,
35), the cDNA of normal human TDP-43 and its mutant form (M337V substitution) was created by PCR
and was cloned into CAG expression vector. Linearized transgene constructs were injected into the pronuclei of fertilized eggs of C57BL/6J mice. Transgenic
mice were identified by PCR amplification of the
human TDP-43 transgene with the following primers:
5’-TGCGGGAGTTCTTCTCTCAG-3’ (forward) and
5’-AGCCACCTGGATTACCACCA-3’ (reverse). Dual-mutant α-synuclein transgenic mice were received
from Dr. Richfield and were genotyped by PCR analysis as described in the original publications (34, 36).
All transgenic mice were maintained on C57BL6 genomic background.
Mouse psychomotor activity was measured by
Rotarod test as described previously (35, 37). Mice
were tested on a rotating Rotarod (Med Associates)
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twice a week since three months of age. On a testing
day, a mouse was tested three times separated by 10
minutes of rest and was allowed to run on a rotating
Rotarod with accelerated speeds for a maximal period
of five minutes. The average time of three tests was
calculated as the latency to fall from rotating rotarod.

Immunoblotting
Mouse tissues were homogenized in RAPI buffer
supplied with protease inhibitors (Promega). Tissue
lysates were cleared by centrifugation and proteins in
cleared lysates were measured by BCA assay (Pierce).
Total proteins of 25 µg in each lysate were separated
on 10% SDS-PAGE and were blotted onto PVDF
membrane. The immunoreactivity of both human and
mouse TDP-43 was detected with a polyclonal antibody (1: 500; Proteintech) and the immunoreactivity
of human TDP-43 was detected with a mouse monoclonal antibody (1: 1000; Abnova, 2E2-D3). Comparable loading of total proteins among samples was estimated by probing the same membranes with a
mouse monoclonal antibody recognizing mouse
glyceraldehyde-3-phosphatedehydrogenase (1: 2000;
Abnova). Immunoreactivity was visualized by ECL
reaction (Pierce).

Toluidine blue staining
As described in our publication (32), the ventral
and dorsal nerve roots of TDP-43 transgenic mice
were examined for axon degeneration by toluidine
blue staining. Mice were anesthetized and perfused
with a mixture of 4% PFA and 2% glutaraldehyde in
0.1 M phosphate buffer (pH 7.4). The L4 ventral and
dorsal roots were removed and post-fixed in the same
fixative at 4°C overnight. The roots were further fixed
in 1% osmium tetroxide in 0.1 M phosphate buffer
(pH 7.4) for 1 h. The well-fixed tissues were dehydrated in graded ethanol and were embedded in Epon
812 (Electron Microscopic Sciences, Fort Washington,
PA). Nerve roots were transversely cut into 1
µm-thick sections. Axons in the nerve roots were
examined in the semi-thin sections under a light microscope (Nikon 80i).

Immunostaining and histology
Mouse tissues were fixed in 4% PFA and were
cryopreserved in 30% sucrose. On a Cryostat, mouse
brain was cut into coronal sections of 20 µm and
mouse spinal cord was cut into traverse sections of 15
µm. Human TDP-43 immunoreactivity was detected
by incubating tissue sections with a monoclonal antibody specific for human TDP-43 (1: 500; Abnova,
2E2-D3) and was visualized using an ABC kit in
combination with diaminobenzidine (Vector). Immunostained sections were lightly counterstained
http://www.biolsci.org
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with hematoxylin to display the nuclei. Double-labeling immunofluorescence staining was performed as described previously (32). The following
antibodies were used for immunofluorescence staining: mouse monoclonal antibody to human TDP-43 (1:
500; Abnova, 2E2-D3), chicken antibody to ubiquitin
(1: 1000; Sigma), rabbit antibody to tyrosine hydroxylase (TH; Pel-Freez; 1:1000), and mouse monoclonal
antibody to human α-synuclein (1: 1000; Abcam,
4B12). Frozen sections of the gastrocnemius muscle
were stained with hematoxylin and eosin (H&E) to
display tissue structures.

and every fourth section was immunostained for TH.
The number of TH-positive neurons in the SNpc was
estimated with fractionator-based stereology software
(Stereologer), which was run on a PC computer attached to a Nikon 80i microscope with a motorized
XYZ stage (Prior). The number of cortical neurons in
the frontal cortex was also estimated by stereological
cell counting as described previously (39).

Stereological cell counting

To develop a genetic animal model for
TDP-43-linked ALS and FTLD, we created transgenic
mice expressing the human TDP-43 with or without a
pathogenic mutation (Fig. 1).

As described in our publication (38), the number
of dopaminergic neurons in the SNpc was estimated
by stereological cell counting. PFA-fixed mouse midbrain was cut on a Cryostat into four series of sections

3. Results
Overexpression of a mutant TDP-43 causes early
death in transgenic founders

Figure 1: Expression of human TDP-43 in transgenic mice. a, Schematic shows the structure of human TDP-43
transgene. The transgene constructs consist of the CAG promoter, the first noncoding exon and the first intron of the
chicken beta actin gene, the human TDP-43 cDNA with or without pathogenic mutation (M337V substitution), and the three
repeats of SV40 polyadenylation signal. b, PCR analysis identified transgenic founders carrying the normal or the mutant
(M337V) human TDP-43 transgene (hTDP-43). C+: positive control; C-: negative control. c, Immunoblotting detected a
robust expression of human TDP-43 in the forebrain of transgenic founder mice. NG: nontransgenic mouse brain. d, Photo
showing a transgenic founder mouse and its nontransgenic littermate (NG) at 7 days of age. e, Immunoblotting detected a
robust expression of human TDP-43 in the central nerve system of normal TDP-43 transgenic mice. Each lane was loaded
with 25 µg of total protein. The same membrane was first probed with a TDP-43 antibody recognizing both human and
mouse TDP-43 and was then probed with a GAPDH antibody. Muscle: skeletal muscle; hippo: hippocampus.

http://www.biolsci.org

Int. J. Biol. Sci. 2011, 7
The hybrid promoter CAG is shown to drive
transgene expression robustly and ubiquitously in
rodents (35, 40, 41), and thus it was used to drive
TDP-43 transgenes in mice (Fig. 1a). We chose M337V
substitution as an example of TDP-43 mutations because this mutant causes typical ALS with a middle-age onset of symptoms (18). We obtained four
transgenic founders expressing mutant TDP-43M337V
and one founder expressing normal TDP-43 (Fig. 1).
These transgenic founders were born of normal sizes;
three TDP-43M337V founders lost mobility soon after
birth and died within 10 days of birth (Fig. 1d). One
TDP-43M337V female founder lived to 4 months of age,
but it was infertile and died shortly after immobility
was observed. We examined this mutant founder for
neuronal and axonal degeneration in the spinal cord
and nerve roots, but did not detect a significant loss of
spinal motor neurons or motor axons. Similar to our
finding in transgenic rats (32), constitutive overexpression of mutant TDP-43 in mice caused severe
phenotypes in transgenic founders, preventing
transgenic lines from establishment. By contrast, the
transgenic founder overexpressing normal TDP-43
was healthy and fertile.
To expand the normal TDP-43 transgenic mouse
colony, we crossed the transgenic founder with
C57BL6/J mice newly purchased from Jackson Laboratories. Unexpectedly, some male transgenic mice
of the first three generations died within a week after
immobility was observed. No detectable phenotype
was observed in TDP-43 transgenic mice beyond the
fourth generation. We examined the sick mice and did
not detect a degeneration of spinal motor neurons or
motor axons. The copy number of human TDP-43
transgene was unaltered through mouse generations
examined (all 22 copies). We maintained a C57BL6
colony derived from a mating pair that was purchased from the Jackson Laboratories four years ago,
and we created TDP-43 transgenic mice on the genomic background of this mouse colony. The genomic
background of TDP-43 transgenic mice could thus be
considered congenic, but unidentified environmental
or genetic factors may alter phenotypic expression in
our TDP-43 transgenic mice.

Overexpression of the normal TDP-43 causes
cortical neuron degeneration in transgenic mice
TDP-43-positive inclusion is a hallmark of sporadic ALS and FTLD (42, 43), suggesting that TDP-43
may be involved in the pathogenesis of the sporadic
diseases. We used TDP-43 transgenic mice of the sixth
generation for the following experiments. A robust
expression of human TDP-43 was detected in the
brain, spinal cord, and skeletal muscles of TDP-43
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transgenic mice (Figs. 1e, 2b, 3b, and 3c), but not in the
tissues of nontransgenic controls (Figs. 2a and 3a). On
a homogenous genomic background, TDP-43 transgenic mice did not develop abnormality in psychomotor activity by age of one year (Fig. 2c). Accordingly, TDP-43 transgenic mice did not develop detectable pathology in the spinal motor neurons (Fig.
2d-2e), in the dorsal and ventral nerve roots (Fig.
2f-2i), and in the skeletal muscles (Fig. 2j-2k). Mutation of TDP-43 is also linked to FTLD (44). Altered
expression of normal TDP-43 may affect cortical neurons in transgenic animals (32). We assessed cortical
and hippocampal neurons by an unbiased method—stereological cell counting and detected a significant loss of cortical neurons in the transgenic mice at
advanced ages (Fig. 3d-3i). Ubiquitinated TDP-43 aggregates are common to sporadic ALS and FTLD (42,
43). We examined these pathologies in TDP-43 transgenic mice, but did not detect typical TDP-43 or
ubiquitin aggregates in the brain and spinal cord of
the aged mice (Fig. 4a-4l). Consistent with our findings in TDP-43 transgenic rats (32), ubiquitin and
TDP-43 aggregation is not essential to neuronal death.

Overexpression of normal TDP-43 potentiates
alpha-synuclein toxicity to dopaminergic neurons
in transgenic mice
TDP-43 proteinopathy is observed in a wide
range of neurodegenerative diseases including PD
(12, 13). Transient overexpression of TDP-43 in the
substantia nigra causes dopaminergic neuron death
(33). Alpha-synuclein is a major component of Lewy
body characteristic of PD and pathogenic mutation of
α-synuclein is implicated in PD pathogenesis (22-26).
We further examined whether TDP-43 modifies
α-synuclein toxicity in the double transgenic mice. In
TDP-43 transgenic mice, a substantial number of dopaminergic neurons expressed human TDP-43 as
shown by double-labeling immunofluorescence
staining (Fig. 5a-5f). Overexpression of human
TDP-43 alone did not induce a significant loss of dopaminergic neurons in the transgenic mice (Fig. 5q).
We then crossed TDP-43 transgene onto a mutant
α-synuclein transgenic background (Fig. 5g-5l). Previous study showed that overexpression of mutant
α-synuclein causes a significant loss of dopaminergic
neurons in male mice at advanced ages (34); however,
we did not detect a significant loss of dopaminergic
neurons in the mutant α-synuclein transgenic mice
though a trend of neuronal loss was observed (Fig.
5q). Our result does not contradict the previous study
because we examined three male and three female
α-synuclein transgenic mice. Male mice appeared
more sensitive to mutant α-synuclein toxicity than

http://www.biolsci.org
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female mice. In our study, statistical significance
might be obscured by a limited number of animals
and a mixture of male and female mice. Interestingly,
simultaneous overexpression of normal TDP-43 and
mutant α-synuclein caused a significant loss of do-
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paminergic neurons in the transgenic mice as compared to either single transgenic control (Fig. 5m-5q),
suggesting that TDP-43 potentiated α-synuclein neurotoxicity.

Figure 2: No detectable impairment in the motor system of TDP-43 transgenic mice at advanced ages. a, b,
Immunostaining detected human TDP-43 only in the TDP-43 transgenic mouse (hTDP43), but not in its nontransgenic
control (NT). Cross sections of lumbar spinal cord were immunostained with a monoclonal antibody recognizing human
TDP-43 and the ventral horns of lumbar cords were photographed. c, Rotarod test revealed no difference in psychomotor
activity between the TDP-43 transgenic mice (hTDP43) and the nontransgenic littermates (NT). Each group consisted of 8
mice with equal sex composition. d, e, Cresyl violet staining revealed no significant loss of motor neurons in the lumbar
cords of TDP-43 transgenic mice. f-i, Toluidine blue staining showed the structure of the L4 ventral roots (f, g) and the L4
dorsal roots (h, i) in TDP-43 transgenic mice and their nontransgenic littermates at the age of 11 months. j, k, H&E staining
revealed no atrophy of skeletal muscles in the TDP-43 transgenic mice. Scale bars: a-b and f-k, 20 µm; d-e, 50 µm.

http://www.biolsci.org
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Figure 3: A significant loss of cortical neurons in the frontal cortex of TDP-43 transgenic mice at advanced
ages. a-c, Immunostaining revealed a robust expression of human TDP-43 in the cortex and dentate gyrus of TDP-43
transgenic mouse, but not in the cortex of a nontransgenic control (NT). d-g, Cresyl violet staining showed the neurons in
the frontal cortex (d, e) and hippocampus (f, g). Scale bars: a-e, 20 µm; and f-g, 50 µm. h, i, Stereological cell counting
revealed a significant loss of neurons in the frontal cortex, but not in the dentate gyrus, of TDP-43 transgenic mice. Mice
were 10-12 months old. Data are means + SD (n = 5). * indicates p < 0.05.

Figure 4: Ubiquitin
inclusion
undetectable in TDP-43
transgenic mice at
advanced ages. a-l,
Double-labeling fluorescence
staining
revealed no ubiquitin
inclusion
in
TDP-43-overexpressi
ng cells in transgenic
mice at 10 months of
age. Tissue sections
from TDP-43 transgenic mice (hTDP43)
or the nontransgenic
controls (NT) were
immunostained for
human TDP-43 and
mouse ubiquitin. All
scale bars: 20 µm.

http://www.biolsci.org
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Figure 5: Synergistic effects of TDP-43 and mutant alpha-synuclein on dopaminergic neurons in transgenic
mice. a-f, Double-fluorescence labeling revealed a substantial expression of human TDP-43 in the dopaminergic neurons of
human TDP-43 transgenic mice (hTDP43), but not in the neurons of nontransgenic mice (NT). Coronal sections of the
midbrain were simultaneously immunostained for human TDP-43 and mouse tyrosine hydroxylase (TH, a marker of dopaminergic neurons). g-l, double-labeling fluorescence staining detected a robust expression of a mutant human alpha-synuclein (hSYN) in the dopaminergic neurons of hSYN transgenic mice, but not in the neurons of nontransgenic mice
(NT). m-p, Representative photos of low (m, o) or high (n, p) magnification showing dopaminergic neurons in the substantia
nigra of TDP-43 single (m, n) and TDP-43/hSYN double (o, p) transgenic mice. Scale bars: a-l, n and p, 20 µm; m, o, 80 µm.
q, Stereological cell counting revealed a significant loss of dopaminergic neurons (TH-positive) in the TDP-43 and alpha-synuclein double transgenic mice (SYN/TDP) as compared to nontransgenic (NT) or the single transgenic (hTDP or
SYN) mice at 10-12 months of age. Data are means + SD (n = 4-6). The symbol * indicates p < 0.05 as compared to SYN or
hTDP transgenic mice.

4. Discussion
Consistent with our findings in transgenic rats
(32), pathogenically mutated TDP-43 exhibited higher
toxicity than the wildtype form when overexpressed
in transgenic mice. Normal TDP-43 of elevated expression was sufficient to induce neurotoxicity in vivo.
Moreover, TDP-43 and mutant α-synuclein synergistically induced neurotoxicity when concomitantly
overexpressed in the dopaminergic neurons of transgenic mice, suggesting that neuron death is a con-

vergent outcome of the toxicity of disease factors in
neurodegenerative diseases such as PD.
While the nature of pathogenic mutation in
TDP-43 remains largely unknown, TDP-43 with
pathogenic mutation or elevated expression is neurotoxic in vitro and in vivo (28, 45-48). Pathogenic
mutation of TDP-43 may cause a gain of function, a
loss of function, or a dominant negative effect. The
information available is not sufficient to determine the
nature of TDP-43 mutation. Silencing of TDP-43 expression by RNAi induces neuronal death in culture

http://www.biolsci.org
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(49, 50). Deletion of TDP-43 causes a defect at the
neuromuscular junction in Drosophila melanogaster
(51). Constitutive or temporal deletion of TDP-43 in
mice induces severe phenotypes (52, 53), underscoring the importance of TDP-43 in cellular function. It
remains unclear whether neurodegeneration can be
induced by cell-specific deletion of TDP-43 in conditional knockout mice. Forced overexpression of human TDP-43 in mice deregulates the expression of
mouse endogenous TDP-43 (27). Since it is not known
whether human TDP-43 can function properly in
mouse tissues, addition of normal human TDP-43 to
mouse genome may or may not enhance the functions
of TDP-43. In addition, transgenic overexpression of
mutant TDP-43 is unable to differentiate a gain of
function from a dominant negative effect because
both types of mutation can induce disease in transgenic animals (54-56). Although a more sophisticated
model such as a TDP-43 knockin mouse is required
for determining the natures of TDP-43 mutation, our
results, along with previous findings (27, 28, 45-48, 50,
52, 53), suggest a possible gain of function in TDP-43
mutation. We previously showed that overexpression
of normal TDP-43 does not induce ALS disease in
transgenic rats (32). Consistent with our finding in
rats, overexpression of normal TDP-43 in mice failed
to induce ALS phenotypes. Interestingly, overexpression of normal TDP-43 caused a significant (though
moderate) loss of cortical neurons in asymptomatic
mice at advanced ages. It could not be ruled out that
overexpression of normal TDP-43 may induce cortical
neuron degeneration in aged rats. We will examine
cortical neurons in normal TDP-43 transgenic rats at
advanced ages in a follow-up study.
TDP-43 and α-synuclein are involved in a wide
range of neurodegenerative diseases. While TDP-43
proteinopathy is considered a pathologic hallmark of
ALS and FTLD (7-10), it also coexists with Lewy pathology that is a characteristic of sporadic PD (57-59).
Alpha-synuclein is a major component of Lewy body
and Lewy neurites in PD (57-59). When concomitantly
overexpressed in mice, TDP-43 and mutant
α-synuclein synergistically induced dopaminergic
neurodegeneration. Our finding is not unexpected as
TDP-43 and α-synuclein proteinopathy coexist in patients with neurodegenerative diseases (57-59). Clinically, synucleinopathy is more severe in the cases with
than in the cases without TDP-43 proteinopathy (60).
It remains unclear whether and how disease proteins
(such as TDP-43, α-synuclein, β-amyloid, and tau)
interact to induce degeneration of selected groups of
neurons in patients with neurodegenerative diseases.
Our study has provided in vivo evidence suggesting
that disease proteins such as TDP-43 and α-synuclein
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may play a synergistic role in disease induction in
neurodegenerative diseases.

Acknowledgement
We thank Ms. Dian Wang, Ms. Xiaotao Wei, and
Ms. Zhen Qu for technical assistance.
This work is supported by the National Institutes
of Health (NIH)/National Institute of Neurological
Disorders and Stroke (NS064042 and NS072113 to
X.G.X) and by the National Institutes of
Health/National Institute of Environmental Health
Sciences (ES016760 to X.G.X). The content is solely the
responsibility of the authors and does not necessarily
represent the official view of the NIH institutes.

Conflict of Interests
The authors declare no conflicts of interest.

References
1.

Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM,
Baralle
FE.
TDP-43
binds
heterogeneous
nuclear
ribonucleoprotein A/B through its C-terminal tail: an
important region for the inhibition of cystic fibrosis
transmembrane conductance regulator exon 9 splicing. J Biol
Chem 2005;280(45):37572-37584.
2. Abhyankar MM, Urekar C, Reddi PP. A novel CpG-free
vertebrate insulator silences the testis-specific SP-10 gene in
somatic tissues: role for TDP-43 in insulator function. J Biol
Chem 2007;282(50):36143-36154.
3. Bose JK, Wang IF, Hung L, Tarn WY, Shen CK. TDP-43
overexpression enhances exon 7 inclusion during the survival
of motor neuron pre-mRNA splicing. J Biol Chem
2008;283(43):28852-28859.
4. Ou SH, Wu F, Harrich D, García-Martínez LF, Gaynor RB.
Cloning and characterization of a novel cellular protein,
TDP-43, that binds to human immunodeficiency virus type 1
TAR DNA sequence motifs. J Virol 1995;69(6):3584-3596.
5. Buratti E, Baralle FE. Characterization and functional
implications of the RNA binding properties of nuclear factor
TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem
2001;276(39):36337-36343.
6. Strong MJ, Volkening K, Hammond R, Yang W, Strong W,
Leystra-Lantz C, Shoesmith C. TDP43 is a human low
molecular weight neurofilament (hNFL) mRNA-binding
protein. Mol Cell Neurosci 2007;35(2):320-327.
7. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B,
Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de
Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, et al. TDP-43
mutations in familial and sporadic amyotrophic lateral
sclerosis. Science 2008;319(5870):1668-1672.
8. Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB,
Levitch D, Hatanpaa KJ, White CL, Bigio EH, Caselli R, Baker
M, Al-Lozi MT, Morris JC, Pestronk A, Rademakers R, et al.
TDP-43 A315T mutation in familial motor neuron disease. Ann
Neurol 2008;63(4):535-538.
9. Banks GT, Kuta A, Isaacs AM, Fisher EM. TDP-43 is a culprit in
human neurodegeneration, and not just an innocent bystander.
Mamm Genome 2008;19(5):299-305.
10. Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion
C, Couratier P, Legallic S, Salachas F, Hannequin D, Decousus
M, Lacomblez L, Guedj E, Golfier V, Camu W, Dubois B, et al.
TARDBP
mutations
in
motoneuron
disease
with

http://www.biolsci.org

Int. J. Biol. Sci. 2011, 7

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

frontotemporal
lobar
degeneration.
Ann
Neurol
2009;65(4):470-473.
Lippa CF, Rosso AL, Stutzbach LD, Neumann M, Lee VM,
Trojanowski JQ. Transactive response DNA-binding protein 43
burden in familial Alzheimer disease and Down syndrome.
Arch Neurol 2009;66(12):1483-1488.
Chanson JB, Echaniz-Laguna A, Vogel T, Mohr M, Benoilid A,
Kaltenbach G, Kiesmann M. TDP43-positive intraneuronal
inclusions in a patient with motor neuron disease and
Parkinson's disease. Neurodegener Dis 2010;7(4):260-264.
Markopoulou K, Dickson DW, McComb RD, Wszolek ZK,
Katechalidou L, Avery L, Stansbury MS, Chase BA. Clinical,
neuropathological and genotypic variability in SNCA A53T
familial Parkinson's disease. Variability in familial Parkinson's
disease. Acta Neuropathol 2008;116(1):25-35.
Nishihira Y, Tan CF, Toyoshima Y, Yonemochi Y, Kondo H,
Nakajima T, Takahashi H. Sporadic amyotrophic lateral
sclerosis: Widespread multisystem degeneration with TDP-43
pathology in a patient after long-term survival on a respirator.
Neuropathology 2009; epub.
Machida Y, Tsuchiya K, Anno M, Haga C, Ito T, Shimo Y,
Wakeshima T, Iritani S, Ikeda K. Sporadic amyotrophic lateral
sclerosis with multiple system degeneration: a report of an
autopsy case without respirator administration. Acta
Neuropathol 1999;98(5):512-515.
Tsuchiya K, Sano M, Shiotsu H, Akiyama H, Watabiki S, Taki K,
Kondo H, Nakano I, Ikeda K. Sporadic amyotrophic lateral
sclerosis of long duration mimicking spinal progressive
muscular atrophy exists: additional autopsy case with a clinical
course of 19 years. Neuropathology 2004;24(3):228-235.
Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey
BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K,
Salachas F, Pradat PF, Camu W, Meininger V, Dupre N,
Rouleau GA. TARDBP mutations in individuals with sporadic
and familial amyotrophic lateral sclerosis. Nat Genet
2008;40(5):572-574.
Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B,
Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de
Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, et al. TDP-43
mutations in familial and sporadic amyotrophic lateral
sclerosis. Science 2008;319(5870):1668-1672.
Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W,
Elman LB, Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage
M, Steinbart E, McCluskey L, Grossman M, Neumann M, Wu
IL, et al. TARDBP mutations in amyotrophic lateral sclerosis
with TDP-43 neuropathology: a genetic and histopathological
analysis. Lancet Neurol 2008;7(5):409-416.
Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF,
Stewart H, Kelley BJ, Kuntz K, Crook RJ, Sreedharan J, Vance C,
Sorenson E, Lippa C, Bigio EH, et al. Novel Mutations in
TARDBP (TDP-43) in Patients with Familial Amyotrophic
Lateral Sclerosis. PLoS Genet 2008;4(9):e1000193.
Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion
C, Couratier P, Legallic S, Salachas F, Hannequin D, Decousus
M, Lacomblez L, Guedj E, Golfier V, Camu W, Dubois B, et al.
TARDBP
mutations
in
motoneuron
disease
with
frontotemporal lobar degeneration. Annals of Neurology
2009;65:470-474.
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A,
Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES,
Chandrasekharappa S, Athanassiadou A, Papapetropoulos T,
Johnson WG, et al. Mutation in the alpha-synuclein gene
identified in families with Parkinson's disease. Science
1997;276(5321):2045-2047.
Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S,
Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in

242

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

the gene encoding alpha-synuclein in Parkinson's disease. Nat
Genet 1998;18(2):106-108.
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S,
Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R,
Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, et al.
alpha-Synuclein locus triplication causes Parkinson's disease.
Science 2003;302(5646):841.
Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V,
Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan
M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A.
Alpha-synuclein locus duplication as a cause of familial
Parkinson's disease. Lancet 2004;364(9440):1167-1169.
Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak
P, Agid Y, Durr A, Brice A. Causal relation between
alpha-synuclein gene duplication and familial Parkinson's
disease. Lancet 2004;364(9440):1169-1171.
Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E,
Unger T, Malunda J, Xu Y, Winton MJ, Trojanowski JQ, Lee
VM. Dysregulation of the ALS-associated gene TDP-43 leads to
neuronal death and degeneration in mice. J Clin Invest
2011;121(2):726-738.
Shan X, Chiang PM, Price DL, Wong PC. Altered distributions
of Gemini of coiled bodies and mitochondria in motor neurons
of TDP-43 transgenic mice. Proc Natl Acad Sci U S A
2010;107(37):16325-16330.
Stallings NR, Puttaparthi K, Luther CM, Burns DK, Elliott JL.
Progressive motor weakness in transgenic mice expressing
human TDP-43. Neurobiol Dis 2010;40(2):404-414.
Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43
mutant transgenic mice develop features of ALS and
frontotemporal lobar degeneration. Proc Natl Acad Sci U S A
2009;106(44):18809-18814.
Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I,
Smits V, Ceuterick-de Groote C, Van Broeckhoven C,
Kumar-Singh S. TDP-43 transgenic mice develop spastic
paralysis and neuronal inclusions characteristic of ALS and
frontotemporal lobar degeneration. Proc Natl Acad Sci U S A
2010;107(8):3858-3863.
Zhou H, Huang C, Chen H, Wang D, Landel CP, Xia PY,
Bowser R, Liu YJ, Xia XG. transgenic rat model of
neurodegeneration caused by mutation in the TDP gene. PLoS
Genet 2010;6(3):e1000887.
Tatom JB, Wang DB, Dayton RD, Skalli O, Hutton ML, Dickson
DW, Klein RL. Mimicking Aspects of Frontotemporal Lobar
Degeneration and Lou Gehrig's Disease in Rats via TDP-43
Overexpression. Molecular Therapy 2009;17(4):607-613.
Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK.
Risk factors for dopaminergic neuron loss in human
alpha-synuclein
transgenic
mice.
Eur
J
Neurosci
2004;19(4):845-854.
Zhou H, Huang C, Yang M, Landel CP, Xia PY, Liu YJ, Xia XG.
Developing tTA Transgenic Rats for Inducible and Reversible
Gene Expression. Int J Biol Sci 2009;2(5):171-181.
Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C,
Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ.
Behavioral and neurochemical effects of wild-type and mutated
human alpha-synuclein in transgenic mice. Exp Neurol
2002;175(1):35-48.
Xia XG, Zhou H, Huang Y, Xu Z. Allele-specific RNAi
selectively silences mutant SOD1 and achieves significant
therapeutic benefit in vivo. Neurobiol Dis 2006;23(3):578-586.
Zhou H, Falkenburger BH, Schulz JB, Tieu K, Xu Z, Xia XG.
Silencing of the Pink1 gene expression by conditional RNAi
does not induce dopaminergic neuron death in mice. Int J Biol
Sci 2007;3(4):242-250.
Huang C, Zhou H, Tong J, et al. FUS Transgenic Rats Develop
the Phenotypes of Amyotrophic Lateral Sclerosis and

http://www.biolsci.org

Int. J. Biol. Sci. 2011, 7

40.

41.

42.

43.

44.

45.

46.

47.

48.

49.

50.

51.

52.

53.

54.

Frontotemporal Lobar Degeneration. PLOS Genetics 2011;in
press.
Niwa H, Yamamura K, Miyazaki J. Efficient selection for
high-expression transfectants with a novel eukaryotic vector.
Gene 1991;108(2):193-199.
Novak A, Guo C, Yang W, Nagy A, Lobe CG. Z/EG, a double
reporter mouse line that expresses enhanced green fluorescent
protein
upon
Cre-mediated
excision.
Genesis
2000;28(3-4):147-155.
Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi
MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM,
McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H,
et al. Ubiquitinated TDP-43 in frontotemporal lobar
degeneration and amyotrophic lateral sclerosis. Science
2006;314(5796):130-133.
Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H,
Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43
is a component of ubiquitin-positive tau-negative inclusions in
frontotemporal lobar degeneration and amyotrophic lateral
sclerosis. Biochem Biophys Res Commun 2006;351(3):602-611.
Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion
C, Couratier P, Legallic S, Salachas F, Hannequin D, Decousus
M, Lacomblez L, Guedj E, Golfier V, Camu W, Dubois B, et al.
TARDBPmutations in motoneuron disease with frontotemporal
lobar degeneration. Annals of Neurology 2009;65(4):470-473.
Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, Xu
Y, Neumann M, Trojanowski JQ, Lee VM. Expression Of
TDP-43 C-terminal fragments in vitro recapitulates pathological
features of TDP-43 proteinopathies. J Biol Chem 2009 Mar
27;284(13):8516-24.
Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I,
Smits V, Ceuterick-de Groote C, Van Broeckhoven C,
Kumar-Singh S. TDP-43 transgenic mice develop spastic
paralysis and neuronal inclusions characteristic of ALS and
frontotemporal lobar degeneration. Proceedings of the National
Academy of Sciences 2010;107(8):3858-3863.
Li Y, Ray P, Rao EJ, Shi C, Guo W, Chen X, Woodruff EA,
Fushimi K, Wu JY. A Drosophila model for TDP-43
proteinopathy. Proceedings of the National Academy of
Sciences 2010;107(7):3169-3174.
Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43
mutant transgenic mice develop features of ALS and
frontotemporal lobar degeneration. Proceedings of the National
Academy of Sciences 2009;106(44):18809-18814.
Iguchi Y, Katsuno M, Niwa J, Yamada S, Sone J, Waza M,
Adachi H, Tanaka F, Nagata K, Arimura N, Watanabe T,
Kaibuchi K, Sobue G. TDP-43 depletion induces neuronal cell
damage through dysregulation of Rho family GTPases. J Biol
Chem 2009;284(33):22059-22066.
Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourgouin
P, Rochefort D, Bel Hadj S, Durham HD, Velde CV, Rouleau
GA, Drapeau P. Gain and loss of function of ALS-related
mutations of TARDBP (TDP-43) cause motor deficits in vivo.
Hum Mol Genet 2009;18:18.
Feiguin F, Godena VK, Romano G, D'Ambrogio A, Klima R,
Baralle FE. Depletion of TDP-43 affects Drosophila
motoneurons terminal synapsis and locomotive behavior. FEBS
Lett 2009;583(10):1586-1592.
Chiang PM, Ling J, Jeong YH, Price DL, Aja SM, Wong PC.
Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to
obesity, and alters body fat metabolism. Proc Natl Acad Sci U S
A 2010;107(37):16320-16324.
Wu LS, Cheng WC, Hou SC, Yan YT, Jiang ST, Shen CK.
TDP-43, a neuro-pathosignature factor, is essential for early
mouse embryogenesis. Genesis 2010;15:15.
Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong
S, Wu D, Xue R, Andrade M, Tankou S, Mori S, Gallagher M,

243

55.

56.

57.

58.

59.

60.

Ishizuka K, Pletnikov M, Kida S, et al. Dominant-negative
DISC1 transgenic mice display schizophrenia-associated
phenotypes detected by measures translatable to humans. Proc
Natl Acad Sci U S A 2007;104(36):14501-14506.
Lai C, Lin X, Chandran J, Shim H, Yang W, Cai H. The G59S
mutation in p150(glued) causes dysfunction of dynactin in
mice. J Neurosci 2007;27(51):13982-13990.
Kudo T, Kure S, Ikeda K, Xia AP, Katori Y, Suzuki M, Kojima K,
Ichinohe A, Suzuki Y, Aoki Y, Kobayashi T, Matsubara Y.
Transgenic expression of a dominant-negative connexin26
causes degeneration of the organ of Corti and non-syndromic
deafness. Hum Mol Genet 2003;12(9):995-1004.
Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D,
Hatanpaa KJ, Foong C, White CL, Schneider JA, Kretzschmar
HA, Carter D, Taylor-Reinwald L, Paulsmeyer K, Strider J,
Gitcho M, et al. TDP-43 in familial and sporadic frontotemporal
lobar degeneration with ubiquitin inclusions. Am J Pathol
2007;171(1):227-240.
Leverenz JB, Yu CE, Montine TJ, Steinbart E, Bekris LM,
Zabetian C, Kwong LK, Lee VM, Schellenberg GD, Bird TD. A
novel progranulin mutation associated with variable clinical
presentation and tau, TDP43 and alpha-synuclein pathology.
Brain 2007;130(Pt 5):1360-1374.
Josephs KA, Ahmed Z, Katsuse O, Parisi JF, Boeve BF,
Knopman DS, Petersen RC, Davies P, Duara R, Graff-Radford
NR, Uitti RJ, Rademakers R, Adamson J, Baker M, Hutton ML,
et al. Neuropathologic features of frontotemporal lobar
degeneration with ubiquitin-positive inclusions with
progranulin gene (PGRN) mutations. J Neuropathol Exp
Neurol 2007;66(2):142-151.
Yokota O, Davidson Y, Arai T, Hasegawa M, Akiyama H,
Ishizu H, Terada S, Sikkink S, Pickering-Brown S, Mann DM.
Effect of topographical distribution of α-synuclein pathology
on TDP-43 accumulation in Lewy body disease. Acta
Neuropathol 2010;120(6):789-801.

http://www.biolsci.org

